Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

Table 4 Rates of adverse events

Events/100 PY (95 % CI)	Trimmed population^a			Stratified-matched population
	Rituximab	Anti-TNF	Ratio of	Rituximab	Anti-TNF	Ratio of rates^b
	(n = 265)	(n = 737)	rates^b	(n = 205)	(n = 205)	Ratio of rates^b
Cancer	1.5 (0.0, 3.0)	1.9 (0.8, 3.0)	0.8 (0.3, 2.3)	1.6 (0.5, 4.9)	2.9 (1.2, 7.0)	0.5 (0.1, 2.8)
Infection
All events	37.7 (29.9, 45.5)	41.0 (36.0, 46.0)	0.9 (0.7, 1.2)	38.1 (30.2, 48.0)	44.4 (35.4, 55.5)	0.9 (0.6, 1.2)
Serious infections	1.2 (0.0, 2.7)	2.8 (1.3, 4.3)	0.4 (0.1, 1.3)	2.0 (0.7, 6.3)	4.5 (2.0, 10.0)	0.5 (0.1, 2.1)
Cardiovascular	1.8 (0.2, 3.4)	1.4 (0.5, 2.4)	1.3 (0.4, 4.0)	1.6 (0.5, 4.9)	2.9 (1.2, 7.0)	0.5 (0.1, 2.8)

^aRates in the trimmed population were standardized by age and sex. Confidence intervals were calculated using a Poisson approximation of the standard error. ^bRatio of rituximab/anti-TNF agent rates. Anti-TNF anti–tumor necrosis factor, PY patient-years

ISSN: 1478-6362